Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

Pelin      Armutlu; Muhuttin   Emre   Ozdemir; Sule      Ozdas; Ibrahim   Halil   Kavakli; Metin      Turkay

Letters in Drug Design & Discovery

Author(s): Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli and Metin Turkay

DOI: 10.2174/1570180810906050337

Download PDF Flyer Cite As

Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

Page: [337 - 344] Pages: 8

* (Excluding Mailing and Handling)

Explore Articles

About Journal

For Authors

For Editors

For Reviewers

Abstract

It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.

Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening

Cite As